Text Search: Search by:

Refine your search with filters

Year:

Category:

All

Congress Abstracts

Tools & Skills

Publications

Congress Presentations

Videos & Podcasts

Quicksearch

P385: Predictors of tissue healing in ulcerative colitis patients treated with anti-TNFECCO '16 Amsterdam

Year: 2016

Authors:

N. Viazis*¹, M. Giakoumis¹, G. Bamias², D. Goukos², T. Koukouratos¹, J. Anastasiou¹, K. Katopodi¹, S. Ladas², D. Karamanolis¹

¹Evangelismos Hospital, Gastroenterology Department, Athens, Greece, ²Kapodistrian University of Athens, Laikon Hospital, Academic Department of Gastroenterology, Athens, Greece

P386: Anti-TNF alpha as induction and maintenance therapy in ulcerative colitis patients in the BioColitis Registry in GermanyECCO '16 Amsterdam

Year: 2016

Authors:

B. Bokemeyer*¹, T. Krummenerl², C. Maaser³, J. Büning⁴, R. Atreya⁵, A. Lügering⁶, U. Helwig⁷, P. Jessen⁸, P. Hartmann⁹, S. Schreiber¹⁰

¹Gastroenterology Practice Minden, University Hospital Schleswig-Holstein, Department of General Internal Medicine I, Kiel, Germany, Minden, Germany, ²Gastroenterology Practice, Gastroenterology, Münster, Germany, ³University Teaching Hospital Lüneburg, IBD Outpatient Clinic and Department of Geriatric Medicine, Lüneburg, Germany, ⁴University Hospital Schleswig-Holstein, Campus Lübeck, Medical Department I, Gastroenterology, Lübeck, Germany, ⁵University of Erlangen-Nuremberg, Department of Medicine 1, Erlangen, Germany, ⁶Gastroenterology Practice Münster, Münster, Germany, ⁷Gastroenterology Practice Oldenburg, Oldenburg, Germany, ⁸Gastroenterology Practice, Gastroenterology, Altenholz, Germany, ⁹Gastroenterology Practice, Minden, Germany, ¹⁰Christian-Albrechts-Universität, University Hospital Schleswig-Holstein, Department of General Internal Medicine I, Kiel, Germany

P387: Does standard therapy in paediatric Crohn’s disease really prevent our patients from the need of early initiation of anti-TNF treatment?ECCO '16 Amsterdam

Year: 2016

Authors:

P. Domínguez Sánchez*, G. Pujol Muncunill, S. Pinillos Pison, V. Vila Miravet, J. Martín de Carpi

Unit for the Comprehensive Care of Paediatric Inflammatory Bowel Disease. Department of Paediatric Gastroenterology, Hepatology and Nutrition. Hospital Sant Joan de Déu, Barcelona, Spain

P388: Clinical care pathways are needed to decrease variability in the management of the hospitalised ulcerative colitis patientECCO '16 Amsterdam

Year: 2016

Authors:

S. Shah*, S. Naymagon, B. Cohen, B. Sands, M. Dubinsky

Mount Sinai Hospital, Gastroenterology, New York, New York, United States

P389: The value of oxidative stress parameters to predict histological severity in ulcerative colitisECCO '16 Amsterdam

Year: 2016

Authors:

B. Canbakan*¹, K. Atay¹, E. Koroglu¹, M. Tuncer¹, H. Senturk²

¹Istanbul University Cerrahpasa Medical School, Gastroenterology, Istanbul, Turkey, ²Bezmialem University School of Medicine, Gastroenterology, Istanbul, Turkey

P390: To double dose or not to double dose? That is the question: Single centre experience in the use of infliximab antibodies and levels in a paediatric IBD (pIBD) cohortECCO '16 Amsterdam

Year: 2016

Authors:

B. Huggett*, S. Sider, S. Chadokufa, N. Acton, N. Shah, F. Kiparissi

Great Ormond Street Hospital, London, United Kingdom

P391: Gender differences in adalimumab continuation rates: Results of a Crohn’s disease cohortECCO '16 Amsterdam

Year: 2016

Authors:

M. Lie*, J. Kreijne, J. van der Woude

Erasmus MC, Gastroenterology and Hepatology, Rotterdam, Netherlands

P392: Comparing the accuracy and ease of use of self-administered ‘Malnutrition Universal Screening Tool’ (MUST) to screening by a health care professional using MUST to explore malnutrition rates in an outpatient inflammatory bowel disease clinicECCO '16 Amsterdam

Year: 2016

Authors:

S. Zacharopoulou-Otapasidou*¹, K. Keetarut¹, S. Bloom², S. McCartney²

¹University College London Hospital, Nutrition and Dietetics Department, London, United Kingdom, ²University College London Hospital, Department of Gastroenterology, London, United Kingdom

P393: Investigation of Crohn’s disease patients receiving anti-TNF α therapy after surgery for intestinal stenosisECCO '16 Amsterdam

Year: 2016

Authors:

T. Kuriyama*, B. Iizuka, H. Kashiwagi, T. Hara, A. Ito, T. Omori, M. Yonezawa, K. Tokushige

Tokyo Women’s Medical University, Gastroenterology, Tokyo, Japan

P394: Psychosexual dysfunction in a cohort of Greek inflammatory bowel disease patients in clinical remission: preliminary resultsECCO '16 Amsterdam

Year: 2016

Authors:

D. Xanthis*, K. Soufleris, E. Gavalas, P. Anyfanti, G. Chatzinakos, N. Grammatikos, A. Tsimperidis, O. Giouleme

Aristotle University of Thessaloniki, Second Propedeutic Department of Internal Medicine, Thessaloniki, Greece

P395: Real-life prospective experience with adalimumab in ulcerative colitis in Italy: preliminary results of a pilot studyECCO '16 Amsterdam

Year: 2016

Authors:

M. Daperno*¹, A. Armuzzi², D. Pugliese², A. Lavagna¹, P. Gionchetti³, F. Rizzello³

¹AO Ordine Mauriziano, Gastroenterology Unit, Torino, Italy, ²Complesso Integrato Columbus, Internal Medicine, Roma, Italy, ³AO S. Orsola-Malpighi & University, Internal Medicine, Bologna, Italy

P396: Cyclosporin A efficacy in a paediatric ulcerative colitis: a retrospective single-centre studyECCO '16 Amsterdam

Year: 2016

Authors:

M. Osiecki*, M. Dadalski, J. Kierkus

The Children’s Memorial Health Institute, Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland

P397: Efficacy and safety of sequential rescue therapy with infliximab and tacrolimus in patients with corticosteroid-refractory ulcerative colitisECCO '16 Amsterdam

Year: 2016

Authors:

K. Matsuoka*, E. Saito, T. Fujii, K. Takenaka, F. Iwamoto, M. Kimura, M. Nagahori, K. Ohtsuka, M. Watanabe

Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan

P398: The costs of care for patients with ulcerative colitis: effect of adalimumab on health care resources utilisation in clinical practice from INSPIRADAECCO '16 Amsterdam

Year: 2016

Authors:

S. Travis*¹, B. Feagan², L. Peyrin-Biroulet³, R. Panaccione⁴, S. Danese⁵, A. Lazar⁶, A. Robinson⁷, J. Petersson⁷, M. Bereswill⁶, M. Skup⁷, N. Chen⁷, S. Wang⁷, R. Thakkar⁷, J. Chao⁷

¹Oxford University Hospitals, Oxford, United Kingdom, ²Robarts Research Institute, Ontario, Canada, ³University Hospital of Nancy, Les Nancy, France, ⁴University of Calgary, Calgary, Canada, ⁵Istituto Clinico Humanitas, Milan, Italy, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁷AbbVie Inc., North Chicago, United States

P399: Testing patients initiating anti-TNFα agents for mycobacterial infection using interferon-gamma release assays (IGRA): The combined experience of a large dermatology and Inflammatory Bowel Disease serviceECCO '16 Amsterdam

Year: 2016

Authors:

S. Rajagopal*¹, K. Greveson², S. McBride³, A. Waite³, M. Lipman⁴, C. Murray²

¹University College London, Medicine, London, United Kingdom, ²Royal Free Hospital, Centre for Gastroenterology, London, United Kingdom, ³Royal Free Hospital, Centre for Dermatology, London, United Kingdom, ⁴Royal Free Hospital, Respiratory Medicine, London, United Kingdom

P400: Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD Cohort StudyECCO '16 Amsterdam

Year: 2016

Authors:

T. Greuter*¹, L. Biedermann¹, G. Rogler¹, E. Safroneeva², A. Schoepfer³, S. Vavricka^{1, 4}

¹University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, ²University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland, ³University Hospital Lausanne - CHUV, Division of Gastroenterology and Hepatology, Lausanne, Switzerland, ⁴Triemli Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland

P401: Confocal laser endomicroscopy predicts response in patients with acute inflammatory bowel disease undergoing anti-integrin therapy with vedolizumabECCO '16 Amsterdam

Year: 2016

Authors:

M. Ellrichmann*¹, J. Bethge¹, G. Aust¹, A. Arlt¹, B. Brandt¹, S. Zeissig^{1, 2}, S. Nikolaus¹, K. Aden¹, S. Schreiber¹

¹University Hospital Schleswig-Holstein, Campus Kiel, Medical Department I, Kiel, Germany, ²University Hospital Dresden, Department of Gastroenterology, Dresden, Germany

P402: A novel high-dose mesalazine tablet is as effective as conventional low-dose mesalazine tablets in inducing remission in patients with mildly to moderately active ulcerative colitis (UC): A double-blind, double-dummy, multicentre, randomised trialECCO '16 Amsterdam

Year: 2016

Authors:

A. Dignaß*¹, R. Schnabel², J. Romatowski³, V. Pavlenko⁴, A. Dorofeyev⁵, J. Derova⁶, L. Jonaitis⁷, T. Nacak⁸, R. Greinwald⁸

¹Agaplesion Markus Krankenhaus, Dept. of Medicine I, Frankfurt a.M., Germany, ²Pannónia Magánorvosi Centrum Kft, Budapest, Hungary, ³Gastromed sc, Bialystok, Poland, ⁴Stavropol State Medical University, Stavropol, Russian Federation, ⁵Regional Bowel Diseases Centre of Donetsk State Medical University, Donetsk, Ukraine, ⁶Latvian Maritime Medical Centre, Riga, Latvia, ⁷Lithuanian University of Health Sciences, Dept. of Gastroenterology, Kaunas, Lithuania, ⁸Dr. Falk Pharma GmbH, Clinical Research, Freiburg, Germany

P403: Combined therapy with anti-TNF and immunomodulator is superior to monotherapy for postoperative prophylaxis in Crohn’s disease after intestinal resection: a retrospective analysis from a tertiary centreECCO '16 Amsterdam

Year: 2016

Authors:

A. O’Connor*¹, J. Taylor¹, N. Scott², C. Selinger¹, J. Hamlin¹, A. Ford^{1, 3}

¹Leeds Gastroenterology Institute, Leeds, United Kingdom, ²St James’s University Hospital, Histopathology, Leeds, United Kingdom, ³University of Leeds, Leeds Institute of Biochemical and Clinical Sciences, Leeds, United Kingdom

P404: Real-life experience with golimumab in ulcerative colitis patients according to prior anti-TNF useECCO '16 Amsterdam

Year: 2016

Authors:

C. Taxonera*¹, F. Bertoletti², C. Rodriguez³, I. Marin⁴, J. Arribas⁵, P. Martinez-Montiel⁶, M. Sierra⁷, L. Arias⁸, M. Rivero⁹, A. Juan¹⁰, E. Iglesias¹¹, N. Manceñido¹², J.L. Perez-Calle¹³, A. Algaba¹⁴, M. Barreiro-de Acosta¹⁵, A. Gutierrez¹⁶, F. Argüelles¹⁷, D. Busquets¹⁸, M. Chaparro¹⁹, C. Alba¹, D. Olivares¹, M. Calvo²⁰, J.P. Gisbert¹⁹

¹Hospital Clinico San Carlos, IBD Unit, Madrid, Spain, ²Hospital Santa Creu i Sant Pau, Barcelona, Spain, ³Hospital de Navarra A, Department of Gastroenterology, Pamplona, Spain, ⁴Hospital Gregorio Marañón, Madrid, Spain, ⁵Hospital Ramón y Cajal, Department of Gastroenterology, Madrid, Spain, ⁶University Hospital 12 De Octubre, Department of Gastroenterology, Madrid, Spain, ⁷Hospital de León, Gastroenterology, León, Spain, ⁸Hospital de Burgos, Burgos, Spain, ⁹University Hospital Marques de Valdecilla - HUMV, Department of Gastroenterology, Santander, Spain, ¹⁰Hospital Germans Trias i Pujol, Barcelona, Spain, ¹¹Hospital Reina Sofía, Gastroenterology, Córdoba, Spain, ¹²Hospital Infanta Sofía, Gastroenterology, Madrid, Spain, ¹³Hospital Universitario Fundación Alcorcón, Gastroenterology, Madrid, Spain, ¹⁴Hospital de Fuenlabrada, Gastroenterology, Madrid, Spain, ¹⁵Hospital Clínico de Santiago, Gastroenterology, Santiago de Compostela, Spain, ¹⁶Hospital Universitario de Alicante, Alicante, Spain, ¹⁷Hospital Universitario Virgen Macarena, Sevilla, Spain, ¹⁸Hospital Universitari Dr Trueta, Girona, Spain, ¹⁹Hospital La Princesa, IP and CIBERehd, Gastroenterology, Madrid, Spain, ²⁰Hospital Puerta de Hierro, Gastroenterology, Madrid, Spain